Quick Answer
Protalix BioTherapeutics, Inc. reported Cash and Equivalents of $14.68 million for fiscal year 2025.
Protalix BioTherapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $14.68M | -25.7% |
| 2024 | $19.76M | -16.4% |
| 2023 | $23.63M | +38.1% |
| 2022 | $17.11M | -56.1% |
| 2021 | $38.98M | +113.4% |
| 2020 | $18.27M | +2.7% |
| 2019 | $17.79M | -52.9% |
| 2018 | $37.81M | -26.1% |
| 2017 | $51.16M | -19.1% |
| 2016 | $63.28M | -17.1% |
| 2015 | $76.37M | +39.5% |
| 2014 | $54.77M | -36.6% |
| 2013 | $86.40M | +66.0% |
| 2012 | $52.03M | +92.7% |
| 2011 | $27.00M | -24.8% |
| 2010 | $35.90M | -55.8% |
| 2009 | $81.27M | +90.8% |
| 2008 | $42.60M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $13.65M | -50.2% | -23.7% |
| June 30, 2025 | $17.89M | -23.5% | -8.0% |
| March 31, 2025 | $19.46M | -28.5% | -1.5% |
| December 31, 2024 | $19.76M | -16.4% | -27.9% |
| September 30, 2024 | $27.41M | +34.3% | +17.1% |
| June 30, 2024 | $23.40M | -51.4% | -14.0% |
| March 31, 2024 | $27.21M | -17.6% | +15.1% |
| December 31, 2023 | $23.63M | +38.1% | +15.8% |
- Protalix BioTherapeutics, Inc. showed a decrease of -25.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, Protalix BioTherapeutics, Inc.’s cash and equivalents has declined by 65.5% (from $42.60 million to $14.68 million).
- The most recent figure is from Protalix BioTherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: